Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) : Episode 8
Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression
The panel discusses the importance of thyroid hormone replacement and TSH suppression, highlighting the role of endocrinologists in managing the risk of cardiovascular disease. Dr. Brose also addresses the potential long-term risks associated with radioactive iodine treatment in the post-surgery setting, including cytopenia, salivary gland issues, and excessive tearing of the eyes.
EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends
EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer
EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer
EP: 4.Predisposition for Patients Developing DTC: Age and Gender
EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management
EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies
EP: 7.The Importance of Thyroidectomy in DTC Patient Care
Now Viewing
EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression
EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management
EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned
EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy
EP: 12.Exploring Real-World Evidence Presented at ATA 2023
EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC
EP: 14.Toxicity Profiles for DTC Guidelines Therapies
EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment
EP: 16.Neoadjuvant Approach in RAI-R-DTC
EP: 17.Phase 2 ATLEP Trial Results
EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights
Related Videos
